• Dyne Therapeutics director Brian S. Posner reported an open-market purchase of 2,000 common shares at a weighted average price of $17.08.
• Posner’s direct holdings rose to 15,500 common shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-137998), on April 01, 2026, and is solely responsible for the information contained therein.